欧洲药品管理局人用药品委员会近日发布建议，认为SIGA Technologies Inc公司研发的抗病毒药物特考韦瑞（Tecovirimat）应不再作为猴痘（Mpox）的治疗方案。该机构通过官网声明指出，当前临床证据显示该药物对猴痘病毒的疗效尚未得到充分验证，且潜在风险可能超过治疗获益。
委员会在评估最新流行病学数据与临床试验结果后强调，医疗工作者需转向使用经正式批准且具备明确疗效的替代疗法。此次建议将提交至欧盟委员会作最终裁决，若通过则意味着该药物在欧盟范围内的猴痘治疗适应症将被正式撤销。
欧洲药品管理局人用药品委员会近日发布建议，认为SIGA Technologies Inc公司研发的抗病毒药物特考韦瑞（Tecovirimat）应不再作为猴痘（Mpox）的治疗方案。该机构通过官网声明指出，当前临床证据显示该药物对猴痘病毒的疗效尚未得到充分验证，且潜在风险可能超过治疗获益。
委员会在评估最新流行病学数据与临床试验结果后强调，医疗工作者需转向使用经正式批准且具备明确疗效的替代疗法。此次建议将提交至欧盟委员会作最终裁决，若通过则意味着该药物在欧盟范围内的猴痘治疗适应症将被正式撤销。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.